Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: Comparison of two phase II trials

Clinical Cancer Research

Volumn 4, Issue 11, 1998, Pages 2723-2728

  Felip, Enriqueta ^a   Massuti, Bartomeu ^b   Camps, Carlos ^c   Benito, Dolores ^d   Isla, Dolores ^e   González Larriba, Jose Luis ^f   López Cabrerizo, M Paz ^g   Salamanca, Oscar ^d   Puerto Pica, José ^h   Moyano, Alfredo ⁱ   Baselga, José ^a   Rosell, Rafael ^g  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d BRISTOL MYERS SQUIBB   (United States)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h HOSPITAL INFANTA CRISTINA   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GRANULOCYTOPENIA; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; THERAPY RESISTANCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 0031782882     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J., 311: 899-909, 1995.
2. Rosell, R., Abad-Esteve, A., Moreno, L. Barnadas, A., Carles, J., Fernandez, C., Ribelles, N., and Culubret, N. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer. Cancer (Phila.), 65: 1692-1699, 1990.
3. Rosell, R., Carles, J., Ariza, A., Moreno, I., Ribelles, N., Solano, V., Pellicer, I., Barnadas, A., and Abad, A. A Phase II study of days 1 and 8 cisplatin and recombinant α-2B interferon in advanced non-small cell lung cancer. Cancer (Phila.), 67: 2448-2453, 1991.
4. Kris, M. G., Gralla, R. J., Wertheim, M. S., Kelsen, D. P., O'Connell, J. P., Burke, M. T., Fiore, J. J., Cibas, I. R., and Heelan, R. T. Trial of the combination of mitomycin, vindesine and cisplatin in patients with advanced non-small cell lung cancer. Cancer Treat. Rep., 70: 1091-1096, 1986.
5. Ruckdeschel, J. C., Finkelstein, D. M., Mason, B. A., and Creech, R. M. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, a randomized comparison of four cisplatin-containing regimens. J. Clin. Oncol., 3: 72-79, 1985.
6. Klastersky, J., Sculier, J. P., Ravez, P., Libert, P., Michel, J., Vandermoten, G., Rocmans, P., Bonduelle, Y., Maraisse, M., Michiels, T., Thiriaux, J., Mommen, P., Dalesio, O., and the EORTC Lung Cancer Working Party. A randomized study comparing a high and a standard dose of cisplatin en combination with etoposide in the treatment of advanced non-small cell lung carcinoma. J. Clin. Oncol., 4: 1780-1786, 1986.
7. Rapp, E., Pater, J. L., Willan, A., Cormier, Y., Murray, N., Evans, W. K., Hodson, D. I., Clark, D. A., Feld, R., and Arnold, A. M. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multi-center randomized trial. J. Clin. Oncol., 6: 633-641, 1988.
8. Pazdur, R., Kudelka, A. P., Kavanagh, J. J., Cohen, P. R., and Raber, M. N. The taxoids: paclitaxel (Taxol) and docetaxel (taxotere). Cancer Treat. Rev., 19: 351-386, 1993.
9. Hanauske, A. R., Degen, D., Hilsenbeck, S. G., Bissery, M. C., and von Hoff, D. D. Effects of Taxotere and Taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs, 3: 121-124, 1992.
10. Chang, A. Y., Kim, K., Glick, J., Anderson, T., Karp, D., and Johnson, D. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer. The Eastern Cooperative Oncology Group results. J. Natl. Cancer Inst. (Bethesda), 85: 388-394, 1993.
11. Murphy, W. K., Fossella, F. V., Winn, R. J., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, J., Dhingra, H., and Raber, M. N. Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J. Natl. Cancer Inst. (Bethesda), 85: 384-388, 1993.
12. Rosell, R., Gonzalez-Larriba, J. L., Alberola, V., Molina, F., Monzo, M., Benito, D., Perez, J. M., and de Anta, J. M. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Semin. Oncol., 22 (Suppl. 14): 12-18, 1995.
13. Langer, C. J., Leighton, J. C., Comis, R. L., O'Dwyer, P. J., McAleer, C. A., Bonjo, C. A., Engstrom, P. F., Litwin, S., and Ozols, R. F. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a Phase II toxicity, response and survival analysis. J. Clin. Oncol., 13: 1860-1870, 1995.
14. Johnson, D. H., Paul, D. M., Hande, K. R. Shyr, Y., Blanke, C., Murphy, B., Lewis, M., and DeVore, R. F., III. Paclitaxel plus carboplatin in advanced non-small cell lung cancer: a Phase II trial. J. Clin. Oncol., 14: 2054-2060, 1996.
15. Huizing, M. T., Giaccone, G., van Warmerdam, L. J. C., Rosing, H., Bakker, P. J., Vermorken, J. B., Postmus, P. E., van Zandwijk, N., Koolen, M. G. J., ten Bokkel Huinink, W. W., van der Vijgh, W. J. F., Bierhorst, F. J., Lai, A., Dalesio, O., Pinedo, H. M., Veenhof, C. H. N., and Beijnen, J. H. for the European Cancer Centre. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J. Clin. Oncol., 15: 317-329, 1997.
16. Bunn, P. A. Combination paclitaxel and platinum in the treatment of lung cancer: United States experience. Semin. Oncol., 23 (Suppl. 15): 9-15, 1996.
17. van Maanen, J. M. S., Retel, J., de Vries, J., and Pinedo, H. M. Mechanism of action of antitumor drug etoposide: a review. J. Natl. Cancer Inst. (Bethesda), 80: 1526-1533, 1988.
18. Hahn, S. M., Liebmann, J. E., Cook, J., Fisher, J., Goldspiel, B., Venzon, D., Mitchell, J. B., and Kaufman, D. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro. Cancer (Phila.), 72: 2705-2711, 1993.
19. Perez, E. A., Buckwalter, C. A., and Reid, J. P. Combinations of paclitaxel and etoposide in the treatment of lung cancer. Semin. Oncol., 23 (Suppl. 15): 21-25, 1996.
20. Gianni, L. Theoretical and practical aspects of paclitaxel scheduling. Ann. Oncol., 6: 861-863, 1995.
21. Tolcher, A. W., Cowan, K. H., Noone, M. H., Denicoff, A. M., Kohler, D. R., Goldspiel, B. R., Barnes, C. S., McCabe, M., Gossard, M. R., Zujewski, J., and O'Shaughenessy, J. A. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J. Clin. Oncol., 14: 95-102, 1996.
22. Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Locatelli, A., Bonadonna, G., and Egorin, M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol., 13: 180-190, 1995.
23. Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., Sartorius, S. E., Cornblath, D. R., Hendricks, C. B., and Donehower, R. C. Sequences of Taxol and cisplatin: a Phase I and pharmacologic study. J. Clin. Oncol., 9: 1692-1703, 1991.
24. Kennedy, M. J., Zahurak, K. M. L., Donehower, R. C., Noe, D. A., Sartorius, S., Chen, T. L., Bowling, K., and Rowinsky, E. K. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J. Clin. Oncol., 14: 783-791, 1996.
25. Holmes, F. A., Madden, T., Newman, R. A., Valero, V., Theriault, R. L., Fraschini, G., Walters, R. S., Booser, D. J., Buzdar, A. U., Willey, J., and Hortobagyi, G. N. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a Phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol., 4: 2713-2721, 1996.
26. Gianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., Spreafico, C., Laffranchi, A., Caraceni, A., Martini, C., Stefanelli, M., Valagussa, P., and Bonadonna, G. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J. Clin. Oncol., 13: 2688-2699, 1995.
27. Harris, J. W., Rahman, A., Kim, B. R., Guengerich, F. P., and Collins, J. M. Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res., 54: 4026-4035, 1994.
28. Relling, M. V., Nemec, J., Schuetz, E. G., Schuetz, J. D., Gonzalez, F. J., and Korzekwa, K. R. O-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol. Pharmacol., 45: 352-358, 1994.
29. Boyer, M. J., Zalcberg, J., Olver, I. N., Millward, M. J., Richardson, G., and Mckeage, M. J. Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer. Ann. Oncol., 8: 485-489, 1997.
30. Belotti, D. Paclitaxel (Taxol), a microtubule affecting drug, inhibits tumor induced angiogenesis. Proc. Am. Assoc. Cancer Res., 37: 57, 1996.
31. Ruckdeschel, J., Wagner, H., Williams, C., Heise, M., and Hilstro, J. Second line chemotherapy for resistant metastatic, non-small cell lung cancer: the role of Taxol. Proc. Am. Soc. Clin. Oncol., 13: 357, 1994.
32. Liebmann, J. E., Fisher, J., Teague, D., and Cook, J. A. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol. Res., 6: 25-31, 1994.
33. Kano, Y., Akustu, M., Tsunoda, S., Ando, J., Matsui, J., Suzuki, K., Ikeda, T., Inoue, Y., and Adachi, K. I. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br. J. Cancer, 74: 704-710, 1996.
34. Johnson K. R., Wang, L., Miller, M. C., III, Willingham, M. C., and Fan, W. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells. Clin. Cancer Res., 3: 1739-1745, 1997.
35. Ukena, D., Berg, M., Leutz, M., Zell, L., Schlimmer, P., and Sybrecht, G. W. A Phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC). Lung Cancer, 19: 31-36, 1998.
36. Hainsworth, J. D., Thompson, D. S., and Greco, A. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J. Clin. Oncol., 13: 1609-1614, 1995.
37. Perez, E. A., Coc, T., Turrell, C., Lau, D., Campbell, D., and Gandara, D. Phase I study of paclitaxel with oral etoposide in advanced solid tumors. Cancer J. Sci. Am., 2: 286-290, 1996.
38. Green, M. R., MacManus, D. A., and Lilenbaum, R. C. A Phase I trial of paclitaxel and etoposide for metastatic or recurrent malignancies. Semin. Oncol., 22 (Suppl. 6): 128-131, 1995.